Pharma Finance SRL
Pharma Finance reported total assets of €5.88m at the end of the 2024 financial year (annual accounts filed with the NBB on 31 Aug 2025).
The score of Pharma Finance shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity -16 % Total assets -16 %
Accounts of the company itself (not consolidated).
The full file covers 12 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma Finance's annual accounts
Filed annual accounts
- Year ended 31 Dec 2024filed on 31 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 29 Dec 2022
- Year ended 31 Dec 2020filed on 31 Aug 2021
Pharma Finance's financial analysis
- Solvency37.3%sector median: 41.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma Finance
Pharma Finance's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0462.292.102
- VAT number
- BE0462292102
- Peppol
- Registered · 0208:0462292102 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Dec 1997
- Registered office
- 3140 Keerbergen
- Latest accounts
- 2024 · filed on 31 Aug 2025
- Activity
- Intermediation service activities for real estate activities (NACE 68310)
Pharma Finance (SRL) has been based in Keerbergen since 1997, active in: intermediation service activities for real estate activities. For 2024, it reports a net loss of 97,554 € and equity of €2.19m; its revenue is not published. Its solvency stands at 37.3%, below the median of its sector (41.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharma Finance
Companies in the same business, of comparable size and area, outside its group.
- Centre International de Commerce Intermediation service activities for real estate activities Uccle · balance sheet €6.22m
- Vevaco Intermediation service activities for real estate activities Izegem · balance sheet €5.13m
- Investinspain.XX Intermediation service activities for real estate activities Boortmeerbeek · balance sheet €3.88m
- Vastgoed Gryson Intermediation service activities for real estate activities Torhout · balance sheet €5.96m
- Kwintix Intermediation service activities for real estate activities Damme · balance sheet €5.92m
- Leisure Fund Development of building projects De Panne · balance sheet €3.93m
- New Lavanco Intermediation service activities for real estate activities Anzegem · balance sheet €10.9m
- @T Home Invest Development of building projects Wervik · balance sheet €11.5m
Frequently asked questions about Pharma Finance
What is the revenue of Pharma Finance?
Pharma Finance files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Pharma Finance?
In Belgium, the VAT number is the company number prefixed with BE: BE0462292102 for Pharma Finance, if the company is VAT-registered. Its company number (CBE) is 0462.292.102.
Where is the registered office of Pharma Finance?
According to the CBE register, the registered office of Pharma Finance is in 3140 Keerbergen.
What is the equity of Pharma Finance?
At the close of the 2024 financial year, the equity of Pharma Finance amounts to 2,189,839 €, a solvency of 37.3% of total assets.
Who manages Pharma Finance?
The register lists 2 active mandates at Pharma Finance. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma Finance
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →